CN113499397A - Composition for treating coronary heart disease and preparation method thereof - Google Patents
Composition for treating coronary heart disease and preparation method thereof Download PDFInfo
- Publication number
- CN113499397A CN113499397A CN202111027053.9A CN202111027053A CN113499397A CN 113499397 A CN113499397 A CN 113499397A CN 202111027053 A CN202111027053 A CN 202111027053A CN 113499397 A CN113499397 A CN 113499397A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- heart disease
- coronary heart
- treating coronary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 19
- 239000009636 Huang Qi Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 18
- 241001489091 Ganoderma sinense Species 0.000 claims abstract description 15
- 244000124209 Crocus sativus Species 0.000 claims abstract description 13
- 235000015655 Crocus sativus Nutrition 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 230000008569 process Effects 0.000 claims abstract description 5
- 235000006533 astragalus Nutrition 0.000 claims description 25
- 241000305491 Gastrodia elata Species 0.000 claims description 20
- 241001061264 Astragalus Species 0.000 claims description 15
- 210000004233 talus Anatomy 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 241000045403 Astragalus propinquus Species 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000012467 final product Substances 0.000 claims description 7
- 238000000227 grinding Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 241000208689 Eucommia ulmoides Species 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 241000222336 Ganoderma Species 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 37
- 239000003814 drug Substances 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 17
- 230000036407 pain Effects 0.000 abstract description 17
- 230000001737 promoting effect Effects 0.000 abstract description 17
- 208000002193 Pain Diseases 0.000 abstract description 16
- 210000003734 kidney Anatomy 0.000 abstract description 15
- 210000000952 spleen Anatomy 0.000 abstract description 14
- 210000004185 liver Anatomy 0.000 abstract description 13
- 210000002784 stomach Anatomy 0.000 abstract description 13
- 230000007812 deficiency Effects 0.000 abstract description 12
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 210000000988 bone and bone Anatomy 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 238000005728 strengthening Methods 0.000 abstract description 5
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 4
- 241000208688 Eucommia Species 0.000 abstract description 4
- 208000005392 Spasm Diseases 0.000 abstract description 4
- 208000006673 asthma Diseases 0.000 abstract description 4
- 229940107666 astragalus root Drugs 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 210000002435 tendon Anatomy 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 230000001914 calming effect Effects 0.000 abstract description 3
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 238000001816 cooling Methods 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 210000005259 peripheral blood Anatomy 0.000 abstract description 3
- 239000011886 peripheral blood Substances 0.000 abstract description 3
- 230000008673 vomiting Effects 0.000 abstract description 3
- 238000010792 warming Methods 0.000 abstract description 3
- 206010000087 Abdominal pain upper Diseases 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 210000004916 vomit Anatomy 0.000 abstract description 2
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 14
- 150000004676 glycans Chemical class 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- -1 alantolaldehyde Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- UXDFUVFNIAJEGM-UHFFFAOYSA-N 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1CCC1=CC(OC)=C(OC)C(OC)=C1 UXDFUVFNIAJEGM-UHFFFAOYSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N calycosin Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 4
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- LAWPHHZXTUPSDG-UHFFFAOYSA-N Astragaloside I Natural products CC(=O)OC1C(O)COC(OC2CCC34CC35CCC6(C)C(C)(CCC6(O)C7(C)CCC(O7)C(C)(C)O)C5CC(OC8OC(CO)C(O)C(O)C8O)C4C2(C)C)C1OC(=O)C LAWPHHZXTUPSDG-UHFFFAOYSA-N 0.000 description 3
- KXHCYYSIAXMSPA-UHFFFAOYSA-N Astragaloside-I Chemical compound CC(=O)OC1C(OC(=O)C)C(O)COC1OC1C(C)(C)C2C(OC3C(C(O)C(O)C(CO)O3)O)CC3C4(C)CC(O)C(C5(C)OC(CC5)C(C)(C)O)C4(C)CCC43CC42CC1 KXHCYYSIAXMSPA-UHFFFAOYSA-N 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 3
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 3
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000013974 saffron Nutrition 0.000 description 3
- 239000004248 saffron Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- 241000984061 Aquilaria Species 0.000 description 2
- LVBLYMQWWGLBRE-UHFFFAOYSA-N Astragaloside-II Chemical compound CC(=O)OC1C(C(COC1OC2CCC34CC35CCC6(C(C(CC6(C5CC(C4C2)OC7C(C(C(C(O7)CO)O)O)O)C)O)C8(CCC(O8)C(C)(C)O)C)C)O)O LVBLYMQWWGLBRE-UHFFFAOYSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 2
- RYAHJFGVOCZDEI-UFFNCVEVSA-N Dendrobine Chemical compound C([C@H]1CC[C@@H]2[C@@]31C)N(C)[C@@H]3[C@H]1[C@@H](C(C)C)[C@@H]2C(=O)O1 RYAHJFGVOCZDEI-UFFNCVEVSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229960000796 barbital sodium Drugs 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- HJCCJZGOBHFQSX-UHFFFAOYSA-N cyclosieversioside B Natural products CC(CCC(O)C(C)(C)OC1OC(CO)C(O)C(O)C1O)C2C(CC3(C)C4CC(O)C5C(C)(C)C(CCC56CC46CCC23C)OC7OCC(O)C(O)C7O)OC8OC(CO)C(O)C(O)C8O HJCCJZGOBHFQSX-UHFFFAOYSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- RYAHJFGVOCZDEI-CZKZLRAZSA-N dendrobine Natural products O=C1O[C@@H]2[C@H](C(C)C)[C@H]1[C@H]1[C@@]3(C)[C@@H]2N(C)C[C@H]3CC1 RYAHJFGVOCZDEI-CZKZLRAZSA-N 0.000 description 2
- 229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 235000019633 pungent taste Nutrition 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- SGAWOGXMMPSZPB-UHFFFAOYSA-N safranal Chemical compound CC1=C(C=O)C(C)(C)CC=C1 SGAWOGXMMPSZPB-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000271309 Aquilaria crassna Species 0.000 description 1
- 241000271307 Aquilaria malaccensis Species 0.000 description 1
- 241001533085 Aquilaria sinensis Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- JLKGXASMCRAVAK-UHFFFAOYSA-N Astragaloside-II Natural products CC(=O)OC1C(O)C(O)COC1OC2CCC34CC35CCC6(C)C(C)(CCC6(O)C7(C)CCC(O7)C(C)(C)O)C5CC(OC8OC(CO)C(O)C(O)C8O)C4C2(C)C JLKGXASMCRAVAK-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000328598 Ceiba pubiflora Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- DJHCVWLJAINILQ-UHFFFAOYSA-N Cyclosieversioside D Natural products CC(=O)OC1C(O)C(O)COC1OC2CCC34CC35CCC6(C)C(C(O)CC6(C)C5CC(OC7OC(CO)C(O)C(O)C7O)C4C2(C)C)C8(C)CC(CO8)C(C)(C)O DJHCVWLJAINILQ-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241001002545 Engelhardia roxburghiana Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000305492 Gastrodia Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001113425 Iridaceae Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- LZEPVVDVBJUKSG-UHFFFAOYSA-N Pterocarpan Natural products C1=CC=C2C3COC4=CC=CC=C4C3OC2=C1 LZEPVVDVBJUKSG-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 241000150278 Seoul orthohantavirus Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930187719 Soyasaponin Natural products 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241001534930 Thymelaeaceae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-XZFBGSIGSA-N astragaloside a Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4C([C@@H](O)C(O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XZFBGSIGSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AKGGYBADQZYZPD-UHFFFAOYSA-N benzyl acetone Natural products CC(=O)CCC1=CC=CC=C1 AKGGYBADQZYZPD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- YUHRVKGYFHPWRI-UHFFFAOYSA-N chrysotoxine Natural products COC1=C(O)C(OC)=CC(CCC=2C=C(OC)C(OC)=CC=2)=C1 YUHRVKGYFHPWRI-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 108010012173 hypophysin Proteins 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000010748 inability to lie flat Diseases 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229930195126 picroside Natural products 0.000 description 1
- KEUKDVIGAVVGLF-RUYHYXBRSA-N picroside I Natural products OC[C@]12O[C@H]1[C@@H]3O[C@@H](O[C@@H]4O[C@H](COC(=O)C=Cc5ccccc5)[C@@H](O)[C@H](O)[C@H]4O)C=C[C@@H]3[C@H]2O KEUKDVIGAVVGLF-RUYHYXBRSA-N 0.000 description 1
- AKNILCMFRRDTEY-UHFFFAOYSA-N picroside II Natural products C1=C(O)C(OC)=CC(C(=O)OC2C3C(C(OC=C3)OC3C(C(O)C(O)C(CO)O3)O)C3(CO)OC32)=C1 AKNILCMFRRDTEY-UHFFFAOYSA-N 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 235000017509 safranal Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of Chinese herbal medicines, and discloses a composition for treating coronary heart disease and a preparation method thereof. The composition is prepared from lignum Aquilariae Resinatum, and has effects of activating qi-flowing, relieving pain, warming middle warmer, relieving vomit, and promoting inspiration to relieve asthma; the dendrobium officinale can tonify stomach, promote fluid production, nourish yin, clear heat and enhance the immunity of the organism; astragalus root, radix astragali strengthens the spleen and strengthens the middle warmer, raises yang and lifts sinking, benefits wei and strengthens exterior; rhizoma Gastrodiae has effects of calming endogenous wind, relieving spasm, suppressing liver yang, dispelling pathogenic wind, dredging collaterals, reducing peripheral blood vessel, cerebral vessels and coronary blood vessel resistance, lowering blood pressure, slowing heart rate, relieving pain and resisting inflammation; eucommia bark leaf liver and kidney tonifying medicine and tendon and bone strengthening medicine; the ganoderma sinensis calms nerves and strengthens stomach, and the crocus sativus has the effects of promoting blood circulation and removing blood stasis, cooling blood and removing toxicity. The prescription is mainly prepared from traditional Chinese medicine raw materials which are mild in nature and warm and enter the channels of the stomach, spleen and kidney, and has the effects of improving yang qi, regulating qi, relieving chest stuffiness, regulating heart qi deficiency, treating epigastric pain and coronary heart disease and treating angina pectoris through the optimal dosage ratio. The preparation method has simple steps, safe flow process, no toxic or side effect, convenient taking and convenient carrying.
Description
Technical Field
The invention belongs to the technical field of Chinese herbal medicines, and particularly relates to a composition for treating coronary heart disease and a preparation method thereof.
Background
Coronary heart disease is a short term for coronary atherosclerotic heart disease, also known as ischemic heart disease. It is caused by atherosclerosis of the coronary artery, the blood vessel supplying heart substances, and the atherosclerotic plaque is accumulated on the intima of the coronary artery and seriously narrows or even blocks the lumen of the coronary artery over time, so that the blood flow of the cardiac muscle is reduced, the oxygen supply of the heart is insufficient, and a series of ischemic manifestations are generated. Such as chest distress, angina pectoris, myocardial infarction and even sudden death.
Coronary heart disease is equivalent to thoracic obstruction in traditional Chinese medicine, and has the main symptoms of chest stabbing pain, immobility, worse night and frequent palpitation. Chest distress and pain caused by suffocation, or pain induced to shoulder and back, chest distress, short breath, heavy limbs, obesity and excessive phlegm. Chest pain involving the back, severe cold pain, palpitations, heavy sensation with dyspnea, inability to lie flat, dark purple tongue with greasy coating, deep and unsmooth pulse or slippery pulse.
At present, most patients with coronary heart disease are more willing to select drug therapy compared with surgical therapy and interventional therapy which have great operation pain and high treatment cost.
At present, western medicines or traditional Chinese medicines can be selected for treating coronary heart disease. At present, Chinese patent medicines and Chinese herbal compound medicines are commonly used for treating coronary heart disease in clinic. Western medicines mainly comprise the following categories: aspirin, betalaks, kaiputong, hypolipidemic drugs, nitrate drugs, long-acting or slow-release dihydropyridine calcium antagonists and non-dihydropyridine calcium antagonists. The medicine has certain treatment and alleviation effects, but has limited effect, easy relapse after stopping the medicine, no radical cure of coronary heart disease and certain toxic and side effects.
The traditional Chinese medicine considers that the pathogenesis of coronary heart disease mainly comprises the following points: (1) heart yang deficiency, heart blood stasis: when heart yang is insufficient, the heart yang will be unable to circulate; the heart-blood fails to be pushed by heart-qi, so that the blood circulation is blocked, blood stasis and heart-vessel obstruction can cause the symptoms of heart pain; in addition, yang deficiency causes excessive cold, the channels are urgent, blood is congealed by cold, the channels are obstructed, and angina pectoris is manifested as the onset of cold; (2) spleen deficiency produces phlegm, repressing heart yang: the spleen governs transportation and transformation and is the source of disease. When the spleen yang is insufficient, water dampness can not be transported and transformed, so that phlegm is generated internally, heart yang is blocked, qi and blood circulation is obstructed, and cardiodynia is caused; (3) deficiency of liver-yin and kidney-yin, decline of heart-qi, stagnation of heart-blood: five zang organs mutually restrict and mutually generate, kidney yang deficiency, liver yin deficiency, wood failure to generate fire, heart qi deficiency, inability to promote blood circulation, and blood obstruction of meridians can cause heart pain.
The traditional Chinese medicine considers that the functions of the medicinal materials are respectively long and biased, and if a single medicine is reused, the expected effect is difficult to achieve, even adverse reactions are difficult to avoid, so the scientific and reasonable compatibility of the traditional Chinese medicines is important.
The traditional Chinese medicine for treating coronary heart disease mainly emphasizes the functions of promoting blood circulation to remove blood stasis and regulating qi to alleviate pain, and can obtain a certain treatment effect, but the curative effect is not stable enough, and the aim of curing cannot be achieved.
Disclosure of Invention
In order to solve the above problems in the prior art, the present invention aims to provide a composition for treating coronary heart disease and a preparation method thereof.
The technical scheme adopted by the invention is as follows: the composition for treating coronary heart disease is mainly prepared from the following raw materials in parts by mass:
2-5 parts of agilawood, 6-12 parts of dendrobium officinale, 10-20 parts of astragalus membranaceus, 3-10 parts of gastrodia elata, 15-30 parts of folium cortex eucommiae, 10-22 parts of ganoderma sinensis and 3-8 parts of crocus sativus.
Agilawood and the name of the traditional Chinese medicine. Is resin-containing wood derived from Aquilaria agallocha Roxb. and Aquilaria sinensis (Lour.) Gilg of Aquilaria of Thymelaeaceae. Has effects of activating qi-flowing, relieving pain, warming middle-jiao, relieving vomit, and absorbing qi and relieving asthma. It can be used for treating chest and abdomen distention and pain due to cold accumulation and qi stagnation, stomach cold emesis, and asthma due to kidney deficiency. Pungent and bitter taste, slightly warm in nature; it enters spleen, stomach and kidney meridians. Chemical components: contains volatile oil and resin, etc., and contains Aquilaria acid, alantolaldehyde, linalool, lignum Aquilariae Resinatum alcohol, benzyl acetone, furan lignum Aquilariae Resinatum alcohol, etc., and phenolic component. The pharmacological action is as follows: 1. effects on the digestive system: the agilawood has an inhibiting effect on the rabbit off-body small intestine movement; the volatile oil has effects of promoting digestive juice secretion and bile secretion. 2. Effects on the cardiovascular system: the agilawood can obviously resist rat myocardial ischemia caused by hypophysin and enhance the hypoxia tolerance of mice; has blood pressure lowering effect. 3. Effects on the nervous system: the lignum Aquilariae Resinatum has effects of prolonging sleep time and relieving spasm. 4. In addition, the agilawood has certain effects of anesthesia, pain relief, muscle relaxation and the like; the Chinese eaglewood decoction has strong inhibiting effect on human tubercle bacillus, typhoid bacillus and shigella flexneri.
Dendrobium officinale, the name of traditional Chinese medicine. Is dried stem of Dendrobium officinale Kimura et Migo, an Orchidaceae plant. Has effects of benefiting stomach, promoting fluid production, nourishing yin and clearing heat. It can be used for treating fever with body fluid deficiency, dry mouth, polydipsia, stomach yin deficiency, anorexia, retching, asthenia heat after illness, hyperactivity of fire due to yin deficiency, bone steaming, fatigue, dim eyesight, and flaccidity of tendons and bones. Sweet in taste and slightly cold in nature; it enters stomach and kidney meridians. Chemical components: the stem contains polysaccharide, alkaloids such as dendrobine, cupronite, dendrobine and the like, and phenanthrene compounds: chrysophanol and erianin; and also contains various amino acids such as glutamic acid, aspartic acid, glycine, leucine, etc., and microelements such as iron, zinc, manganese, copper, etc. The pharmacological action is as follows: polysaccharides can enhance immunity. Chrysotoxin and erianin can inhibit the activity of liver cancer and ehrlich ascites cancer cells. In addition, it also has antiaging, antitumor, and blood sugar lowering effects.
Astragalus root, name of traditional Chinese medicine. Is root of Astragalus membranaceus (Fisch.) Bge. of Astragalus of Leguminosae, Astragalus membranaceus (Astragalus membranaceus) Bge. var. mongholicus (Bge.) Hsiao or Astragalus membranaceus (Fisch.) Bge. Has effects in invigorating spleen, strengthening middle warmer, invigorating yang, lifting sink, invigorating defensive qi, consolidating superficial resistance, promoting urination, removing toxic materials, and promoting granulation. It is mainly indicated for spleen qi deficiency syndrome, lung qi deficiency syndrome, qi deficiency spontaneous sweating syndrome, qi and blood deficiency, ulcer and sore difficult to ulcerate and rot, or difficult to heal for a long time. Sweet in flavor and slightly warm in nature; it enters spleen and lung meridians. Chemical components: separating astragaloside I, astragaloside II, daucosterol, beta-sitosterol, palmitic acid, astragaloside A, B, C, 2', 4' -dihydroxy-5, 6-dimethoxy isoflavan, ursolic acid, choline, betaine, folic acid, calycosin, formononetin and astragaloside I, II, III, IV using triterpene cycloastragaloside as aglycone from radix astragali. The antibacterial component is L-3-hydroxy-9-methoxyl pterocarpan. The Mongolian radix astragali contains soyasaponin, astragalosides I, II, IV, and daucosterol. Contains three kinds of homogeneous polysaccharides including astragalus polysaccharide I, astragalus polysaccharide II and astragalus polysaccharide III, and has two kinds of dextran AG-1 and AG-2 separated and two kinds of heteropolysaccharide AH-l and AH-2 separated. AG-1 and AH-1 have immune promoting effect. Contains flavonoids such as formononetin and calycosin; it also contains 21 amino acids such as asparagine, canavanine, proline and Yttrium, etc., and 14 trace elements such as iron, manganese, zinc and rubidium. The pharmacological action is as follows: 1. impact on the immune system: the components such as astragalus root and polysaccharide thereof can obviously improve the nonspecific immunity function; has promoting or enhancing effects on humoral immunity, cellular immunity, etc.; has obvious stimulation effect on an interferon system, and has the effects of self-induction, activity volatilization and the like. 2. Effects on cellular metabolism: the astragalus can obviously delay the natural aging process of the human embryo diploid cell and can prolong the cell life by about 1/3; at high concentrations, it has an inhibitory effect on the mitosis of lymphocytes cultured in healthy humans in vitro, while at low concentrations it has a promoting effect 3 on the cardiovascular system: the astragaloside 50-200 μ g/ml has positive inotropic effect on heart, and 30 μ g/ml has negative inotropic effect; radix astragali has blood pressure lowering effect. 4. The antibacterial effect is as follows: radix astragali has antibacterial effect on Shigella shigella, Bacillus anthracis, alpha-hemolytic streptococcus, beta-hemolytic streptococcus, Bacillus diphtheriae, Pseudomonas diphtheriae, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus citreus, Staphylococcus albus, and Bacillus subtilis. 5. The antiviral effect is as follows: the radix astragali injection has certain blocking effect on the infection process of the epidemic hemorrhagic fever virus. Radix astragali has effect in inhibiting viruses including HIV at a certain concentration. The decoction has effects of inactivating virus directly, inhibiting cytopathy after virus infection, inhibiting varicella-zoster virus directly, and inhibiting growth of virus. 6. Effects on the blood system: the astragalus decoction has the effects of improving the reduction of hemolytic blood deficiency animal cell volume, the reduction of blood specific viscosity, the reduction of erythrocyte electrophoresis rate, the prolongation of electrophoresis time and the like caused by the acetophenylhydrazine. 7. Effects on the urinary system: the radix astragali injection has kidney protecting effect; huang Qi has the moderate diuretic effect. 8. Effects on sugar metabolism: the Astragalus polysaccharides has the function of regulating blood sugar in two directions. 9. In addition, radix astragali has antiaging, mutation resisting, liver protecting, fatigue relieving, anoxia resisting, cold resisting, radioprotective, antitumor, pulmonary hypertension resisting, tranquilizing, pain relieving, intelligence improving, antiinflammatory, and hormone-like effects.
Gastrodia elata, name of traditional Chinese medicine. Is dried tuber of Gastrodia elata Bl. of Gastrodia of Orchidaceae. Has effects of calming endogenous wind, relieving spasm, suppressing liver yang, dispelling pathogenic wind, and dredging collaterals. It can be used for treating stirring of liver-wind, convulsive epilepsy, convulsion, vertigo, headache, numbness of limbs, hemiplegia, and rheumatalgia. Sweet in taste and neutral in nature; it enters liver meridian. Chemical components: the product contains gastrodine, gastrodine aglycone, beta-sitosterol, daucosterol, citric acid, monomethyl ester, palmitic acid, succinic acid, sucrose, etc.; it also contains rhizoma Gastrodiae polysaccharide, vitamin A, various amino acids, trace alkaloids, and various trace elements such as chromium, manganese, ferrum, cobalt, nickel, copper, and zinc. The pharmacological action is as follows: the water and alcohol extracts of the gastrodia elata and different preparations can obviously reduce the spontaneous activity of mice, prolong the sleeping time of the mice caused by barbital sodium and cyclohexene barbital sodium, inhibit or shorten the attack time of experimental epilepsy, the gastrodia elata also reduces the resistance of peripheral blood vessels, cerebral blood vessels and coronary blood vessels, and has the functions of reducing blood pressure, slowing down heart rate, relieving pain and resisting inflammation, and the gastrodia elata polysaccharide has immunological activity.
Eucommia ulmoides leaves, which are plants of the family eucommia ulmoide, are called silk floss trees, silk floss barks and yu si barks, and have the same effective components and pharmacological action as eucommia ulmoides barks. The source is richer, the cost is lower, and the development and utilization prospect is better. The plant taxonomy belongs to the genus eucommia of family eucommia, only one of which belongs to the genus eucommia, and is extremely rare. And (4) efficacy classification: liver and kidney tonifying medicine; a muscle and bone strengthening drug; hypotensive drugs. Nature and taste: slightly pungent; and (4) temperature. The functions and indications are as follows: tonify liver and kidney, strengthen tendons and bones. Can be used for treating deficiency of liver and kidney, dizziness, soreness of waist and knees, and flaccidity of tendons and bones. Meridian tropism: entering the liver; the kidney channel. The main treatment is as follows: low back pain; soreness and weakness of the feet and knees; hypertension.
Ganoderma sinensis, name of Chinese medicinal material. Is fruiting body of Ganoderma Sinense Zhao, Xu et Zhang of Polyporaceae. Has effects of tranquilizing mind, invigorating stomach, and tonifying body. It can be used for treating neurasthenia, insomnia, anorexia, and asthenia due to prolonged illness. Slightly bitter taste and warm nature. Chemical components: the fruiting body and mycelium contains protein, amino acids, saccharides, coumarin, steroid and triterpene compounds. The fruiting body contains oil, wax, and volatile and sublimable substances.
Crocus sativus, named as traditional Chinese medicine. The product is stigma of croci Sativi of Iridaceae. In the middle and last ten days of 10-11 months, picking flowers in the morning of sunny days, picking stigma indoors, and drying in the sun or at low temperature. The main functional indications are as follows: promoting blood circulation, removing blood stasis, cooling blood, removing toxic substance, resolving stagnation, and tranquilizing mind. Can be used for treating amenorrhea, puerperal stagnation, toxic heat, speckle, melancholy, stuffiness, palpitation, and mania. Mild in nature and sweet in taste. Chemical components: contains crocin-1, 2, 3, 4 (crocin-1-4), picroside (picrococin), dimethyl crocetinate (crocetin), alpha-crocetin (a-crocetin) crocetin (safranal), and volatile oil.
Preferably, the composition is mainly prepared from the following raw materials in parts by mass:
2.5-4 parts of agilawood, 8-11 parts of dendrobium officinale, 12-18 parts of astragalus membranaceus, 5-8 parts of gastrodia elata, 19-26 parts of eucommia ulmoides leaves, 12-20 parts of ganoderma sinensis and 4-6 parts of crocus sativus.
Preferably, the composition is mainly prepared from the following raw materials in parts by mass:
3.5 parts of agilawood, 10 parts of dendrobium officinale, 15 parts of astragalus membranaceus, 6 parts of gastrodia elata, 24 parts of folium cortex eucommiae, 17 parts of ganoderma sinensis and 5 parts of crocus sativus.
A method for preparing a composition for treating coronary heart disease, the method comprising the steps of:
soaking lignum Aquilariae Resinatum, folium Eucommiae, Ganoderma and stigma croci Sativi at a certain ratio, decocting, and filtering to obtain extractive solution;
selecting dendrobium officinale, astragalus and gastrodia elata according to corresponding proportion, mixing, grinding and sieving for later use;
mixing the above extractive solutions with powders of herba Dendrobii, radix astragali and rhizoma Gastrodiae, granulating, and grading to obtain final product.
Preferably, the soaking solvent is water;
the soaking time is 20-40 minutes.
Preferably, the decoction temperature is 80-100 ℃.
Preferably, the decoction period is 30-45 minutes.
Preferably, the filtering is performed by using a sieve with 800-.
Preferably, the dendrobium officinale, the astragalus and the gastrodia elata are mixed, ground and sieved, and then sieved by a 1500-2000-mesh sieve.
Preferably, the finished product is 3-5g per granule.
The invention has the beneficial effects that:
the invention provides a composition for treating coronary heart disease, which is prepared from agilawood, pungent and bitter taste and mild in nature; the medicine has the effects of invigorating spleen, stomach and kidney channels, promoting qi circulation, relieving pain, warming middle-jiao, preventing vomiting, promoting inspiration, relieving asthma, and has strong inhibiting effect on human tubercle bacillus, typhoid bacillus and shigella flexneri; dendrobium officinale, sweet in taste and slightly cold in nature; the Chinese medicinal composition has the effects of tonifying stomach and kidney channels, promoting the production of body fluid, nourishing yin, clearing heat and enhancing immunity of organisms; astragalus root, sweet in flavor, slightly warm in nature; invigorating spleen and lung channel, invigorating spleen and spleen, invigorating yang, consolidating superficial resistance, promoting urination, removing toxic materials, and promoting granulation; gastrodia elata with sweet taste and mild nature; entering liver meridian, calming endogenous wind and relieving spasm, suppressing liver yang, dispelling pathogenic wind and dredging collaterals, reducing resistance of peripheral blood vessel, cerebral vessels and coronary blood vessels, lowering blood pressure, slowing heart rate, relieving pain and resisting inflammation; eucommia ulmoides leaves, a liver and kidney tonifying medicine; a muscle and bone strengthening drug; hypotensive drugs. Nature and taste: slightly pungent; the nature and the temperature; ganoderma sinensis, slightly bitter in taste, warm in nature, tranquilization, invigorating stomach, nourishing and strengthening body, and stigma croci Sativi. Promoting blood circulation, removing blood stasis, cooling blood, removing toxic substance, resolving stagnation, and tranquilizing mind.
The prescription of the composition mainly takes traditional Chinese medicine raw materials which are mild in nature and warm and enter the channels of the stomach, spleen and kidney as main materials, and achieves the effects of improving yang qi, regulating qi, relieving chest stuffiness, conditioning insufficiency of heart qi, treating epigastric pain and coronary heart disease and treating angina pectoris through the optimal dosage proportion.
The preparation method of the composition has the advantages of simple steps, safe process, no toxic or side effect, convenient administration and convenient carrying.
Detailed Description
The present invention is further illustrated below with reference to specific examples. It will be appreciated by those skilled in the art that the following examples, which are set forth to illustrate the present invention, are intended to be part of the present invention, but not to be construed as limiting the scope of the present invention. The reagents used are all conventional products which are commercially available.
Example 1:
a method for preparing a composition for treating coronary heart disease comprises the following steps:
2 g of agilawood, 15 g of folium cortex eucommiae, 10 g of ganoderma sinensis and 3 g of crocus sativus are selected according to corresponding proportion, soaked in water for 20 minutes, decocted at 80 ℃ for 45 minutes and filtered by a 800-mesh filter screen to obtain an extracting solution for later use;
selecting 6 g of dendrobium officinale, 10 g of astragalus and 3 g of gastrodia elata according to corresponding proportion, mixing, grinding and screening by a 1500-mesh screen for later use;
mixing the above extractive solutions with powders of herba Dendrobii, radix astragali and rhizoma Gastrodiae, granulating, and grading to obtain final product.
Example 2:
a method for preparing a composition for treating coronary heart disease comprises the following steps:
selecting 5g of agilawood, 30 g of folium cortex eucommiae, 22 g of ganoderma sinensis and 8 g of saffron according to corresponding proportions, soaking in water for 40 minutes, decocting for 30 minutes at 100 ℃, and screening by a 1200-mesh screen to obtain an extracting solution for later use;
selecting 12 g of dendrobium officinale, 20 g of astragalus and 10 g of gastrodia elata according to corresponding proportion, mixing, grinding and screening by a 2000-mesh screen for later use;
mixing the above extractive solutions with powders of herba Dendrobii, radix astragali and rhizoma Gastrodiae, granulating, and grading to obtain final product.
Example 3:
a method for preparing a composition for treating coronary heart disease comprises the following steps:
selecting 2.5 g of agilawood, 19 g of folium cortex eucommiae, 12 g of ganoderma sinensis and 4 g of saffron according to corresponding proportions, soaking in water for 20 minutes, decocting at 80 ℃ for 45 minutes, and sieving by a 800-mesh sieve to obtain an extracting solution for later use;
selecting 8 g of dendrobium officinale, 12 g of astragalus and 5g of gastrodia elata according to corresponding proportion, mixing, grinding and screening by a 1500-mesh screen for later use;
mixing the above extractive solutions with powders of herba Dendrobii, radix astragali and rhizoma Gastrodiae, granulating, and grading to obtain final product.
Example 4:
a method for preparing a composition for treating coronary heart disease comprises the following steps:
selecting 4 g of agilawood, 26 g of folium cortex eucommiae, 20 g of ganoderma sinensis and 6 g of saffron according to corresponding proportions, soaking in water for 40 minutes, decocting at 100 ℃ for 30 minutes, and screening by a 1200-mesh screen to obtain an extracting solution for later use;
selecting 11 g of dendrobium officinale, 18 g of astragalus and 8 g of gastrodia elata according to corresponding proportion, mixing, grinding and screening by a 2000-mesh screen for later use;
mixing the above extractive solutions with powders of herba Dendrobii, radix astragali and rhizoma Gastrodiae, granulating, and grading to obtain final product.
Example 5:
a method for preparing a composition for treating coronary heart disease comprises the following steps:
selecting 3.5 g of agilawood, 24 g of folium cortex eucommiae, 17 g of ganoderma sinensis and 5g of crocus sativus according to corresponding proportions, soaking in water for 20 minutes, decocting at 80 ℃ for 45 minutes, and sieving by a 800-mesh sieve to obtain an extracting solution for later use;
selecting 10 g of dendrobium officinale, 15 g of astragalus and 6 g of gastrodia elata according to corresponding proportion, mixing, grinding and screening by a 1500-mesh screen for later use;
mixing the above extractive solutions with powders of herba Dendrobii, radix astragali and rhizoma Gastrodiae, granulating, and grading to obtain final product.
The administration mode is as follows: the oral administration dose is no more than 30-50g per day.
The present invention is not limited to the above alternative embodiments, and any other products in various forms can be obtained by the present invention, and the present invention is within the protection scope of the present invention. The above embodiments should not be construed as limiting the scope of the present invention, and it will be understood by those skilled in the art that modifications may be made to the technical solutions described in the above embodiments, or equivalent substitutions may be made to some or all of the technical features thereof, without departing from the scope of the present invention, and at the same time, such modifications or substitutions may not make the essence of the corresponding technical solutions depart from the scope of the embodiments of the present invention.
Claims (10)
1. The composition for treating coronary heart disease is characterized by being prepared from the following raw materials in parts by mass:
2-5 parts of agilawood, 6-12 parts of dendrobium officinale, 10-20 parts of astragalus membranaceus, 3-10 parts of gastrodia elata, 15-30 parts of folium cortex eucommiae, 10-22 parts of ganoderma sinensis and 3-8 parts of crocus sativus.
2. The composition for treating coronary heart disease according to claim 1, wherein the composition is prepared from the following raw materials in parts by mass:
2.5-4 parts of agilawood, 8-11 parts of dendrobium officinale, 12-18 parts of astragalus membranaceus, 5-8 parts of gastrodia elata, 19-26 parts of eucommia ulmoides leaves, 12-20 parts of ganoderma sinensis and 4-6 parts of crocus sativus.
3. The composition for treating coronary heart disease according to claim 2, wherein the composition is prepared from the following raw materials in parts by mass:
3.5 parts of agilawood, 10 parts of dendrobium officinale, 15 parts of astragalus membranaceus, 6 parts of gastrodia elata, 24 parts of folium cortex eucommiae, 17 parts of ganoderma sinensis and 5 parts of crocus sativus.
4. A process for the preparation of a composition for the treatment of coronary heart disease according to any of claims 1 to 3, said process comprising the steps of:
soaking lignum Aquilariae Resinatum, folium Eucommiae, Ganoderma and stigma croci Sativi at a certain ratio, decocting, and filtering to obtain extractive solution;
selecting dendrobium officinale, astragalus and gastrodia elata according to corresponding proportion, mixing, grinding and sieving for later use;
mixing the above extractive solutions with powders of herba Dendrobii, radix astragali and rhizoma Gastrodiae, granulating, and grading to obtain final product.
5. The method for preparing the composition for treating coronary heart disease according to claim 4, wherein the soaking solvent is water;
the soaking time is 20-40 minutes.
6. The method for preparing a composition for treating coronary heart disease according to claim 4, wherein the decocting temperature is 80-100 ℃.
7. The method for preparing a composition for treating coronary heart disease according to claim 6, wherein the decoction period is 30-45 minutes.
8. The method as claimed in claim 4, wherein the filtering is performed with a 1200-mesh screen of 800-.
9. The method for preparing a composition for treating coronary heart disease as claimed in claim 4, wherein the Dendrobium officinale, the radix astragali and the rhizoma Gastrodiae are mixed, ground and sieved, and then sieved through 1500-2000 mesh sieve.
10. The method for preparing the composition for treating coronary heart disease according to claim 4, wherein the finished product is 3-5g per granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111027053.9A CN113499397A (en) | 2021-09-02 | 2021-09-02 | Composition for treating coronary heart disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111027053.9A CN113499397A (en) | 2021-09-02 | 2021-09-02 | Composition for treating coronary heart disease and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113499397A true CN113499397A (en) | 2021-10-15 |
Family
ID=78016396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111027053.9A Pending CN113499397A (en) | 2021-09-02 | 2021-09-02 | Composition for treating coronary heart disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113499397A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530144A (en) * | 2009-04-16 | 2009-09-16 | 何霖 | Glossy ganoderma health tea |
| CN103893571A (en) * | 2014-03-07 | 2014-07-02 | 西藏和藤藏医药开发有限公司 | Medicinal composition for treating hypertension and application thereof |
| CN105878905A (en) * | 2016-06-15 | 2016-08-24 | 段晓辉 | Traditional Chinese medicine composition for treating hypertension, coronary heart diseases, apoplexy and hypoimmunity |
-
2021
- 2021-09-02 CN CN202111027053.9A patent/CN113499397A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530144A (en) * | 2009-04-16 | 2009-09-16 | 何霖 | Glossy ganoderma health tea |
| CN103893571A (en) * | 2014-03-07 | 2014-07-02 | 西藏和藤藏医药开发有限公司 | Medicinal composition for treating hypertension and application thereof |
| CN105878905A (en) * | 2016-06-15 | 2016-08-24 | 段晓辉 | Traditional Chinese medicine composition for treating hypertension, coronary heart diseases, apoplexy and hypoimmunity |
Non-Patent Citations (1)
| Title |
|---|
| 吴德芸: "益气活血化淤法治疗冠心病102例", 《辽宁中医杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102847061B (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN111587942A (en) | Instant tea powder of sixteen kinds of natural Chinese herbal medicine and its prepn and use | |
| CN1762454A (en) | Chinese traditional medicinal composition for treating psoriasis | |
| CN105456428A (en) | Traditional Chinese medicine formula for inhibiting regrowth of tumor cells and preparation method thereof | |
| CN113499397A (en) | Composition for treating coronary heart disease and preparation method thereof | |
| CN1211434A (en) | Oral liquid for resisting altitude stress and its preparation method | |
| CN114522213A (en) | Herbal atomized composition for improving memory and preparation method thereof | |
| CN1385191A (en) | Medicine for treating liver disease | |
| CN1180821C (en) | Medicine for treating cerebral thrombus and its prepn | |
| CN1182858C (en) | Heart-nourishing tea capsule and its prepn | |
| CN113730514A (en) | Compound wine composition beneficial to improving immunity and preparation method and using method thereof | |
| CN113785981A (en) | Health-preserving medicinal and edible composition and preparation method thereof | |
| CN105434598A (en) | Traditional Chinese medicine composition for preventing and treating hypertension, preparation method thereof and preparation | |
| CN105055657A (en) | Spraying agent for improving pain caused by wisdom teeth and preparation method thereof | |
| CN1089845A (en) | A kind of oral medicine and medicine for external use and production method thereof for the treatment of bone disease | |
| CN1085439A (en) | A kind of anticancer herbal drug | |
| WO2018090848A1 (en) | Chinese medicine granule for invigorating spleen, removing obstruction in collaterals and detoxification | |
| CN1899546A (en) | Medicinal composition for treating hepatitis B | |
| CN105770081A (en) | Composition preparation used for promoting healing after cerebral hemorrhage operation and preparation method thereof | |
| CN106728866A (en) | A kind of health protection tea for treating physically weak cough and preparation method thereof | |
| CN104887825A (en) | Traditional Chinese medicine prescription for curing eczema and preparation method thereof | |
| CN110575514A (en) | Traditional Chinese medicine composition for treating chap | |
| CN117599124A (en) | Traditional Chinese medicine composition for treating urticaria | |
| CN102058849B (en) | Application of Tibetan medicine composite to preparing alcohol withdrawal medicines | |
| CN114404517A (en) | Composition for gout and reducing uric acid and application and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211015 |
|
| RJ01 | Rejection of invention patent application after publication |